AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
oleh: Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden, Gary A. Ulaner, Alice Gosselin, Sylvaine Cartot-Cotton, Patrick Cohen, Séverine Doroumian, Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E. Ming, Nils Ternès, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-07-01 |
Deskripsi
There is a need for potent and non-toxic estrogen receptor (ER) antagonists to overcome the limitations of existing endocrine therapies. Here the authors report the results from Arm 1 of the Phase 1/2 study (AMEERA-1) among postmenopausal women with ER+/HER2− advanced breast cancer, which evaluates the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of amcenestrant administered as monotherapy.